Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Officers & Directors Bios

William A. Carter, M.D.
Chairman of the Board, Chief Executive Officer

Dr. Carter, the co-inventor of Ampligen®, joined the Company in 1978, and has served as the Company's Chief Scientific Officer since May 1989, the Chairman of the Company's Board of Directors since January 1992, the Company's Chief Executive Officer since July 1993, the Company's President since April, 1995, and a director since 1987. From 1987 to 1988, Dr. Carter served as the Company's Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. In this context, he received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. From 1985 to October 1988, Dr. Carter served as the Company's Chief Executive Officer and Chief Scientist. He received his M.D. degree from Duke University and underwent his post-doctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahneman Medical University, a position he held from 1980 to 1998. He also served as Director of Clinical Research for Hahneman Medical University's Institute for Cancer and Blood Diseases, and as a professor at Johns Hopkins School of Medicine and the State University of New York at Buffalo. He is a Board certified physician and author of more than 200 scientific articles, including the editing of various textbooks on anti-viral and immune therapy.
Back

   

Anthony Bonelli
President, Chief Operating Officer


 

ANTHONY BONELLI was most recently President and CEO and a member of the Board of Directors of Optigenex, Inc. (OTC BB: OPGX). Optigenex is an applied DNA sciences company dedicated to introducing innovative, clinically proven, proprietary products to the medical, personal care and wellness market. Prior to joining Optigenex as COO in 2004, Mr. Bonelli was president of Anthony Bonelli Associates, Inc., a health care consulting and advisory firm whose clients included major pharmaceutical, biotech, managed care and investment banking firms.

 

Mr. Bonelli has over twenty-five years of diversified healthcare industry experience a

number of which have been spent at the President/Chief Operating Officer level. Until early 1999, he was Chief Operating Officer of Vita Q!test, International, Inc., a custom manufacturer of vitamins and nutritional supplements, and President of its Garden State Nutritionals and Windmill Consumer Products Divisions. From 1995-98 he was President and Chief Operating Officer of Neuman Health Services Inc., a $2.5 BB diversified healthcare provider (distributor, PBM, software, retail chain pharmacy, professional pharmacy services). From 1993-late 1994, he was President and Chief Operating Officer of Copley Pharmaceuticals (a wholly owned subsidiary of Hoechst), a major international generic drug manufacturer. Earlier in his career (1987-93), he served in numerous progressively responsible positions with the Parke Davis Group of Warner-Lambert Company, culminating with his role as Sr. Vice President, Institutional Health Care SBU with North American responsibility for the Business Unit's marketing, sales and manufacturing. His career began with Schering-Plough Corporation in 1972 where until 1987 he held numerous sales/marketing manager and director positions.

 

Mr. Bonelli is a graduate of Harvard University  with a BSin Biological Sciences,holds an MBA in Marketing/Finance from Rutgers University Graduate School of Business and a JD from the University Of San Francisco"School Of Law.


Back
 

 

Robert E. Peterson
Chief Financial Officer
 

Mr. Peterson has served as Chief Financial Officer of the Company since April 1993 and served as an independent financial advisor to the Company from 1989 to April 1993. Also, Mr. Peterson has served as Vice President of the Omni Group, Inc., a business consulting group based in Tulsa, Oklahoma since 1985.From 1971 to 1984, Mr. Peterson worked for PepsiCo, Inc. and served in various financial management positions including Vice President and Chief Financial Officer of PesiCo Foods International and PepsiCo Transportation, Inc. Mr. Peterson is a graduate of Eastern New Mexico University.
Back
 

David R. Strayer, M.D. 
Medical Director - Regulatory Affairs
 

Dr. Strayer, who served as Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University, has acted as the Medical Director of the Company since 1986. He is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. Dr. Strayer has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972. 
Back

 

 
Carol A. Smith, Ph.D. 
Director of Process Development
 

Dr. Smith has served as the Company's Director of Manufacturing and Process Development since April 1995, as Director of Operations since 1993 and as the Manager of Quality Control from 1991 to 1993, with responsibility for the manufacture, control and chemistry of Ampligen®. Dr. Smith has also been Scientist/Quality Assurance Officer for Virotech International, Inc. from 1989 to 1991 and Director of the Reverse Transcriptase and Interferon Laboratories and a Clinical Monitor for Life Sciences, Inc. from 1983 to 1989. She received her Ph.D. from the University of South Florida College of Medicine in 1980 and was an NIH post-doctoral fellow at the Pennsylvania State University College of Medicine. 
Back
 

Ransom W. Etheridge 
Director
 

Mr. Etheridge was elected a director of the Company in October 1997. Mr. Etheridge first became associated with the Company in 1980 when he provided consulting services to the Company and participated in negotiations with respect to the Company's initial private placement through Oppenheimer & Co., Inc. He has been practicing law since 1967, specializing in corporate law. Mr. Etheridge is a member of the Virginia State Bar, a Judicial Remedies Award Scholar and has served as President of the Tidewater Arthritis Foundation. He is a graduate of Duke University, the Wharton School Business Real Estate Investment Analysis Seminar, and the University of Richmond School of Law. 
Back

 


Iraj E. Kiani, N.D., Ph.D.
Director

 

IRAJ E. KIANI, M.B.A., Ph.D., was appointed to the Board of Directors on May 1, 2002. Dr. Kiani is a citizen of England and resides in Newport, California. Dr. Kiani served in various local government position including the Governor of Yasoi, Capital of Boyerahmand, Iran. In 1980, Dr. Kiani moved to England, where he established and managed several trading companies over a period of some 20 years. Dr. Kiani is a planning and logistic specialist who is now applying his knowledge and experience to build a worldwide immunology network, which will use the Company's proprietary technology. Dr. Kiani received his Ph.D. degree from the University of Ferdosi in Iran.
Back
 

William M. Mitchell, M.D. 
Director 

William M. Mitchell, M.D. has been a director of ours since July 1998. Mr. Mitchell is a Professor of Pathology at Vanderbilt University School of Medicine. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as an Intern in Internal Medicine, followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts dealing with viruses and anti-viral drugs. Dr. Mitchell has worked for and with many professional societies, including the International Society for Interferon Research, and committees, among them the National Institutes of Health, AIDS and Related Research Review Group. Dr. Mitchell previously served as a director of Hemispherx from 1987 to 1989. 
Back
 

Richard C. Piani
Director

Mr. Piani has served as a Director of the Company since May 1995. Mr. Piani has been employed as a principal delegate for Industry to the City of Science and Industry, Paris, France, a billion dollar scientific and educational complex since 1995. Mr. Piani provided consulting to the Company in 1993, with respect to general business strategies for the Company's European operations and markets. He served as Chairman of Industrielle du Batiment-Morin, a building materials corporation, from 1986 to 1993. Previously he was Professor of International Strategy at Paris Dauphine University from 1984 to 1993. From 1979 to 1985 Mr. Piani served as Group Director in Charge of International and Commercial Affairs for Rhone-Poulenc and from 1973 to 1979 was Chairman and Chief Executive Officer of Societe "La Cellophane", the French company which invented cellophane and several other worldwide products. Mr. Piani has a Law degree from Facilite de Droit, Paris Sorbonne and a Business Administration degree from Ecola des Hautes Etudes Commerciales, Paris. 
Back
 


Back
 

 

 

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.